VIVO - Meridian Bioscience, Inc.
11.66 0.00 (0.00%)
After hours: 4:51PM EDT
| Previous Close | 11.52 |
| Open | 11.55 |
| Bid | 11.62 x 3100 |
| Ask | 12.35 x 2900 |
| Day's Range | 11.50 - 11.81 |
| 52 Week Range | 10.77 - 19.84 |
| Volume | 216,398 |
| Avg. Volume | 373,979 |
| Market Cap | 497.049M |
| Beta (3Y Monthly) | 0.12 |
| PE Ratio (TTM) | 18.22 |
| EPS (TTM) | 0.64 |
| Earnings Date | Jul 30, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2019-02-01 |
| 1y Target Est | 10.67 |
- Zacks•12 hours ago
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•14 days ago
Meridian Bioscience to Hold Third Quarter 2019 Financial Results Conference Call on July 30, 2019
CINCINNATI, July 10, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report third quarter 2019.
CNW Group•22 days agoInMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors
OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis technology for cannabinoid-based pharmaceuticals to treat severe diseases, today announced the appointment of Catherine Sazdanoff , JD, to its Board of Directors. Ms. Sazdanoff joins InMed's Board with 35 years of experience in the healthcare industry.
- Insider Monkey•27 days ago
Here’s What Hedge Funds Think About Meridian Bioscience, Inc. (VIVO)
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc. (NASDAQ:VIVO) was in […]
- American City Business Journals•2 months ago
One of Cincinnati’s largest public company’s closes on $50M acquisition
Meridian Bioscience has completed a cash acquisition of a Canadian provider of molecular diagnostic instruments and assays.
- GlobeNewswire•2 months ago
Meridian Bioscience Announces Closing of Transaction to Acquire Business of GenePOC
CINCINNATI, June 03, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has.
- Simply Wall St.•2 months ago
Meridian Bioscience, Inc. (NASDAQ:VIVO) Earns Among The Best Returns In Its Industry
Today we are going to look at Meridian Bioscience, Inc. (NASDAQ:VIVO) to see whether it might be an attractive...
- Market Realist•3 months ago
How Does Planet 13’s Valuation Multiple Compare with Peers?
Why Planet 13 Stock Fell ~6.8% on May 7(Continued from Prior Part)Valuation multipleThe increase in Planet 13 Holdings (PLTH) (PLNHF) stock price since the beginning of 2019 has led to a rise in its valuation multiple. As of May 7, the company was
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of VIVO earnings conference call or presentation 30-Apr-19 2:00pm GMT
Q2 2019 Meridian Bioscience Inc Earnings Call
- American City Business Journals•3 months ago
Cincinnati public company could pay $120M for Canadian firm
One of Greater Cincinnati’s largest public companies is planning an acquisition that could have a price tag of up to $120 million.
- Business Wire•3 months ago
Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition
Meridian Bioscience, Inc. today announced financial results for the second quarter and first six months ended March 31, 2019.
- Zacks•3 months ago
Meridian Bioscience (VIVO) Q2 Earnings and Revenues Top Estimates
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 26.67% and 0.46%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire•3 months ago
Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform
Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays. Founded in 2007, GenePOC has approximately 100 employees and generated total revenues of less than $1 million in calendar 2018. Meridian has agreed to make a cash payment at closing of the transaction of $50 million with future payments totaling up to an additional $70 million contingent upon the successful achievement of certain technical development milestones and sales thresholds.
- Associated Press•3 months ago
Meridian Bioscience: Fiscal 2Q Earnings Snapshot
On a per-share basis, the Cincinnati-based company said it had profit of 17 cents. Earnings, adjusted for costs related to mergers and acquisitions and non-recurring costs, were 19 cents per share. The ...
- Simply Wall St.•3 months ago
A Look At The Intrinsic Value Of Meridian Bioscience, Inc. (NASDAQ:VIVO)
Does the April share price for Meridian Bioscience, Inc. (NASDAQ:VIVO) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's val...
- GlobeNewswire•3 months ago
Meridian Launches a New Inhibitor Tolerant qPCR Reagent to Significantly Simplify Molecular Diagnostic Workflows From Crude Samples
CINCINNATI, April 18, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of its Inhibitor-tolerant qPCR Mix, a novel mix to accelerate workflows and.
- Market Realist•3 months ago
How Does MedMen’s Valuation Multiple Compare with Its Peers?
MedMen Announces Preliminary Q3 Revenues(Continued from Prior Part)Valuation multipleSince the beginning of 2019, MedMen Enterprises (MMEN) (MMNFF) has fallen by 3.6% as of April 12. The decline in MedMen’s stock price has also lowered its
- Market Realist•3 months ago
MedMen Announces Preliminary Q3 Revenues
MedMen Announces Preliminary Q3 RevenuesThird-quarter performance Today, MedMen Enterprises (MMEN) (MMNFF) posted an unaudited revenue of $36.60 million for the third quarter of fiscal 2019, which ended on March 30, 2019. Year-over-year, the
- GlobeNewswire•3 months ago
Meridian Bioscience to Hold Second Quarter 2019 Financial Results Conference Call on April 30, 2019
CINCINNATI, April 10, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report second quarter.
- GlobeNewswire•4 months ago
Meridian Bioscience Announces Preliminary Second Quarter 2019 Revenue Results; Updates Fiscal 2019 Guidance
Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary sales results for its second fiscal quarter and revised financial guidance for fiscal 2019. The Company expects second fiscal quarter 2019 revenues to be approximately $50.0 million, compared to $56.5 million in the second fiscal quarter of 2018. This decline is being driven by Diagnostics segment revenues, which are expected to be down approximately 14% to 16% for the quarter, and relatively flat revenues for the Life Science segment compared to the second fiscal quarter of 2018.
- Simply Wall St.•4 months ago
Why Meridian Bioscience, Inc.’s (NASDAQ:VIVO) Cash Is A Factor You Need To Consider
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Two important questions to ask before you buy Meridian Bioscience, Inc. (NASDAQ:VIVO) is, how it makes money and how it spend...
